Experienced in Bladder Cancer

Dr. James L. Bailen

Urology
101 Hospital Blvd., 
Jeffersonville, IN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Bladder Cancer
101 Hospital Blvd., 
Jeffersonville, IN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James Bailen is an Urologist in Jeffersonville, Indiana. Dr. Bailen is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bladder Cancer, and Enlarged Prostate (BPH). Dr. Bailen is currently accepting new patients.

His clinical research consists of co-authoring 13 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Bladder Cancer.

Specialties
Urology
Licenses
Urology in KY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

101 Hospital Blvd., Jeffersonville, IN 47130

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drug: Abiraterone Decanoate
Study Phase: Phase 1
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
A Randomized, Controlled, Open-Label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients With Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Enrollment Status: Terminated
Publish Date: June 06, 2024
Intervention Type: Drug, Procedure
Study Drug: Mitomycin C
Study Phase: Phase 3
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent
Enrollment Status: Terminated
Publish Date: February 05, 2024
Intervention Type: Drug
Study Drugs: VERU-111, Enzalutamide, Abiraterone, Darolutamide and Apalutamide
Study Phase: Phase 3
Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC
Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC
Enrollment Status: Completed
Publish Date: January 16, 2024
Intervention Type: Drug
Study Drugs: TAVT-45, Zytiga, Prednisone
Study Phase: Phase 3
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Open-Label, Proof-of-Concept and Dose Finding Phase 1b/2 Study of VERU-100 in Men With Advanced Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: VERU-100
Study Phase: Phase 1/Phase 2
A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation
A Pilot Multicenter, Randomized, Double-Blind Study Comparing The Proportion Of Responders to PSD502 and to Placebo Using the PEBEQ In Subjects With Premature Ejaculation
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: PSD502
Study Phase: Phase 2
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Single Arm Study for the Treatment of BPH in Large Prostates (Rezūm XL)
Minimally Invasive Prostatic Vapor Ablation - Multicenter, Single Arm Study for the Treatment of BPH in Large Prostates (Rezūm XL)
Enrollment Status: Terminated
Publish Date: August 10, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: August 28, 2019
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
Enrollment Status: Terminated
Publish Date: August 19, 2019
Intervention Type: Biological
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

13 Total Publications

Prospective Trial of Water Vapor Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia in Subjects with a Large Prostate: 6- and 12-month Outcomes.
Prospective Trial of Water Vapor Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia in Subjects with a Large Prostate: 6- and 12-month Outcomes.
Journal: European urology open science
Published: October 19, 2023
Similar Doctors
Distinguished in Bladder Cancer
Dr. Jamie C. Messer
Urology
Distinguished in Bladder Cancer
Dr. Jamie C. Messer
Urology

University Of Louisville Physicians Inc

401 E Chestnut St, 
Louisville, KY 
 (2.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jamie Messer is an Urologist in Louisville, Kentucky. Dr. Messer is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Reconstructive Urology Surgery, and Cystectomy. Dr. Messer is currently accepting new patients.

Distinguished in Bladder Cancer
Dr. Morris B. Jackson
Urology
Distinguished in Bladder Cancer
Dr. Morris B. Jackson
Urology

First Urology Psc

300 High Point Ct, 
Mount Washington, KY 
 (19.3 miles away)
502-955-6129
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Morris Jackson is an Urologist in Mount Washington, Kentucky. Dr. Jackson is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Kidney Stones, Perirenal Abscess, Carbuncle, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Jackson is currently accepting new patients.

Distinguished in Bladder Cancer
Dr. John B. Eifler
Urology
Distinguished in Bladder Cancer
Dr. John B. Eifler
Urology

First Urology Psc

515 Hospital Dr, Suite 3, 
Shelbyville, KY 
 (28.2 miles away)
502-633-2661
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Eifler is an Urologist in Shelbyville, Kentucky. Dr. Eifler is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Kidney Stones, Perirenal Abscess, Carbuncle, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Eifler is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bailen's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile